Saralasin
Saralasin is a competitive angiotensin II receptor antagonist with partial agonistic activity. The aminopeptide sequence for saralasin differs from angiotensin II at three sites: * At position 1, sarcosine replaces aspartic acid, thereby increasing the affinity for vascular smooth muscle AT II receptors and making sara resistant to degradation by aminopeptidases. * At position 5, isoleucine is replaced by valine * At position 8, phenylalanine is replaced by alanine which leads to a smaller stimulatory effect. Saralasin was used to distinguish renovascular hypertension from essential hypertension Essential hypertension (also called primary hypertension, or idiopathic hypertension) is the form of hypertension that by definition has no identifiable secondary cause. It is the most common type affecting 85% of those with high blood pressure. T ... before its discontinuation in January 1984 because of many false-positive and false-negative reports.Hutchison and Shahan (2004) Reference ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]